• Mashup Score: 4
    Impact of a Novel Digital Therapeutics System on... : Official journal of the American College of Gastroenterology | ACG - 8 month(s) ago

    H. METHODS: We conducted a multicenter, single-arm, 48-week trial in 19 patients with biopsy-confirmed NASH. All patients received a DTx intervention with a newly developed smartphone application. The primary endpoint was change in the nonalcoholic fatty liver disease activity score (NAS) without worsening of liver fibrosis. The secondary endpoints included improvement of the NAS by ≥2 points without worsening of liver fibrosis, change in the body weight, and regression of fibrosis. RESULTS: After the 48-week DTx intervention, improvement of the NAS was observed in 68.4% (13/19) of patients. The mean change in the NAS from baseline to the end of the intervention was −2.05 ± 1.96 (P < 0.001 when compared with the threshold of −0.7). A decrease in the NAS by ≥ 2 points was achieved in 11 (57.9%). The average weight loss at the end of the intervention was 8.3% (P < 0.001). Reduction of the fibrosis stage was observed in 58.3% when the analysis was limited to patients with stage F2/3 fibro

    Source: journals.lww.com
    Categories: Cardiologists1, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of akihiro_nomuryn
      akihiro_nomuryn

      Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial https://t.co/5OKIJ4DKFB Official journal of the American College of Gastroenterology | ACG @AmCollegeGastro #DTx #NASH

  • Mashup Score: 8
    NASH drug treatment development: challenges and lessons - 9 month(s) ago

    Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy for NAFLD, despite numerous clinical trials in the past two decades. Currently, the reason so few drugs have been successful in the treatment of NAFLD in a trial setting is not fully understood.

    Source: www.thelancet.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of LancetGastroHep
      LancetGastroHep

      New Review online — NASH drug treatment development: challenges and lessons, by Tilg, Byrne and Targher A wide range of mechanisms are being studied; ideal #NASH candidates should be safe and hepatoprotective+cardioprotective https://t.co/QiwTPypNUf #MASLD #MASH #LiverTwitter https://t.co/wKnEORh4gV

  • Mashup Score: 0
    Time-restricted eating may be ‘promising management option’ in patients with NAFLD, NASH - 10 month(s) ago

    Modifying the timing of daily energy intake may improve metabolic health and restore natural circadian rhythms among patients with nonalcoholic fatty liver disease, according to a review published in Gut.Citing challenges with drug discovery and a lack of therapeutic agents for NAFLD and nonalcoholic steatohepatitis, Thomas Marjot, MD, of the Oxford Center for Diabetes, Endocrinology and

    Source: www.healio.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealioGastro
      HealioGastro

      #ICYMI from @Gut_BMJ: Time-restricted #eating may be ‘promising management option’ in patients with #NAFLD, #NASH #GITwitter #LiverTwitter #MedTwitter https://t.co/dNrgjGt20d

  • Mashup Score: 12
    Wolters Kluwer Health - 10 month(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Healthcare Professionals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NeilFlochMD
      NeilFlochMD

      RT @scottisaacsmd: Can #NASH Be Surgically Cured? @Ali_Aminian_MD @AlkhouriNaim https://t.co/R5BqTQ2fE9 https://t.co/Mumb4Va1NN

  • Mashup Score: 0
    Endoscopic sleeve gastroplasty an effective option for patients with NASH, obesity - 10 month(s) ago

    Endoscopic sleeve gastroplasty was more effective for weight loss than lifestyle modification alone in patients with nonalcoholic steatohepatitis and obesity, according to a speaker at EASL Congress.“Previous studies show how lifestyle intervention with a reduction of more than 10% of body weight promotes NASH resolution and fibrosis regression,” Javier Abad Guerra, MD, a

    Source: www.healio.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealioGastro
      HealioGastro

      #ICYMI from #EASLCongress (@EASLnews): #Endoscopicsleevegastroplasty an effective option for patients with #NASH, #obesity #LiverTwitter https://t.co/r8VcAso7We

  • Mashup Score: 0
    Endoscopic sleeve gastroplasty an effective option for patients with NASH, obesity - 10 month(s) ago

    Endoscopic sleeve gastroplasty was more effective for weight loss than lifestyle modification alone in patients with nonalcoholic steatohepatitis and obesity, according to a speaker at EASL Congress.“Previous studies show how lifestyle intervention with a reduction of more than 10% of body weight promotes NASH resolution and fibrosis regression,” Javier Abad Guerra, MD, a

    Source: www.healio.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealioGastro
      HealioGastro

      #Endoscopicsleevegastroplasty was more effective for weight loss than lifestyle modification alone in patients with #NASH and #obesity, according to a speaker at #EASLCongress. #LiverTwitter #MedTwitter @EASLnews https://t.co/r8VcAso7We

  • Mashup Score: 0
    Pegozafermin improves fibrosis, shows promise as ‘mainstay treatment’ for NASH - 10 month(s) ago

    Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress. “As a physician, I know how important it is to provide patients with therapies that can be impactful across a broad population of individuals with NASH,

    Source: www.healio.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealioGastro
      HealioGastro

      #Pegozafermin significantly improved #fibrosis without worsening of #NASH, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data presented by @DrLoomba at #EASLCongress. https://t.co/XDpKQqmAKw

  • Mashup Score: 0
    Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement - 10 month(s) ago

    Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results. “Resmetirom is an oral, once-daily liver-targeted [thyroid hormone receptor]-beta- selective agonist in development for NASH,” Stephen A.

    Source: www.healio.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HealioGastro
      HealioGastro

      @DrLoomba @mirumpharma Both 80 mg and 100 mg doses of #resmetirom (@MadrigalPharma) achieved #liver biopsy endpoints at 52 weeks in patients with #NASH and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results. https://t.co/07uZdb0AzJ

Load More